<h2>New advancements in drug manufacturing capabilities</h2>
SYDNEY — Curia has announced a significant expansion of its Glasgow, UK facility, aimed at boosting its sterile drug manufacturing capabilities. The company confirmed today that the expansion is set for completion by early 2027 and will enhance the site’s vial filling and lyophilization capacity.
The Glasgow facility, known for its expertise in formulation and sterile fill-finish, will see the addition of an Annex 1 compliant isolator-based vial filling line. According to <a href=”https://melbourne-insider.au/tag/ron-aungst/” title=”Ron Aungst” rel=”noopener”>Ron Aungst</a>, VP of Drug Product Business Unit Operations, Curia has already obtained crucial equipment to ensure the project remains on schedule without disrupting current operations.
Investment and Technological Improvements
In addition to the physical expansion, Curia has upgraded its cell line development (CLD) platform at its Hopkinton, MA site. The enhancements include IP-free semi-targeted integration technology, which offers a six-fold increase in production titers. <a href=”https://melbourne-insider.au/tag/jamie-grabowski/” title=”Jamie Grabowski” rel=”noopener”>Jamie Grabowski</a>, President of Research & Development at Curia, highlighted the benefits of these advancements, stating they provide a more cost-efficient and faster path for partners progressing through clinical manufacturing.
This development comes amidst a growing demand for advanced biologics manufacturing solutions, as companies seek to streamline the transition from discovery to commercialization. Curia’s move aligns with industry trends focusing on enhancing production efficiency and capacity.
Curia’s strategic expansion in Glasgow and technological upgrades in Hopkinton reflect the company’s commitment to staying at the forefront of the biopharmaceutical industry. By investing in state-of-the-art facilities and innovative technologies, Curia aims to meet the increasing global demand for high-quality <a href=”https://melbourne-insider.au/tag/drug-manufacturing/” title=”drug manufacturing” rel=”noopener”>drug manufacturing</a> services. These initiatives not only strengthen Curia’s market position but also provide significant benefits to their clients seeking reliable partners in drug development and production. The expansion will create new job opportunities and foster economic growth in the regions where Curia operates, further solidifying its role as a leader in the contract development and manufacturing organisation (CDMO) sector.
<p class=”rrp-source-attribution”>Source: <a href=”https://newshub.medianet.com.au/2026/03/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform/144776/” target=”_blank” rel=”nofollow noopener”>newshub.medianet.com.au</a>
<p class=”rrp-related-link”>Related: <a href=”https://melbourne-insider.au/australia-population-growth/”>Australia Faces Uncontrolled Population Growth</a>
Last updated: 29 June 2026, 12:30 pm
